Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

838 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.
Zenz T, Kröber A, Scherer K, Häbe S, Bühler A, Benner A, Denzel T, Winkler D, Edelmann J, Schwänen C, Döhner H, Stilgenbauer S. Zenz T, et al. Among authors: winkler d. Blood. 2008 Oct 15;112(8):3322-9. doi: 10.1182/blood-2008-04-154070. Epub 2008 Aug 8. Blood. 2008. PMID: 18689542 Free article.
miR-34a as part of the resistance network in chronic lymphocytic leukemia.
Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, Kienle D, Winkler D, Dürig J, van Oers MH, Mertens D, Döhner H, Stilgenbauer S. Zenz T, et al. Among authors: winkler d. Blood. 2009 Apr 16;113(16):3801-8. doi: 10.1182/blood-2008-08-172254. Epub 2008 Oct 21. Blood. 2009. PMID: 18941118 Free article.
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, Hallek M, Döhner H, Stilgenbauer S. Zenz T, et al. Among authors: winkler d. Blood. 2009 Sep 24;114(13):2589-97. doi: 10.1182/blood-2009-05-224071. Epub 2009 Jul 30. Blood. 2009. PMID: 19643983 Free article. Clinical Trial.
Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk.
Winkler D, Schneider C, Zucknick M, Bögelein D, Schulze K, Zenz T, Mohr J, Philippen A, Huber H, Bühler A, Habermann A, Benner A, Döhner H, Stilgenbauer S, Mertens D. Winkler D, et al. Haematologica. 2010 Nov;95(11):1880-8. doi: 10.3324/haematol.2010.025734. Epub 2010 Aug 16. Haematologica. 2010. PMID: 20713460 Free PMC article.
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.
Edelmann J, Holzmann K, Miller F, Winkler D, Bühler A, Zenz T, Bullinger L, Kühn MW, Gerhardinger A, Bloehdorn J, Radtke I, Su X, Ma J, Pounds S, Hallek M, Lichter P, Korbel J, Busch R, Mertens D, Downing JR, Stilgenbauer S, Döhner H. Edelmann J, et al. Among authors: winkler d. Blood. 2012 Dec 6;120(24):4783-94. doi: 10.1182/blood-2012-04-423517. Epub 2012 Oct 9. Blood. 2012. PMID: 23047824 Free article.
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
Schnaiter A, Paschka P, Rossi M, Zenz T, Bühler A, Winkler D, Cazzola M, Döhner K, Edelmann J, Mertens D, Kless S, Mack S, Busch R, Hallek M, Döhner H, Stilgenbauer S. Schnaiter A, et al. Among authors: winkler d. Blood. 2013 Aug 15;122(7):1266-70. doi: 10.1182/blood-2013-03-488197. Epub 2013 Jul 2. Blood. 2013. PMID: 23821658 Free article. Clinical Trial.
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Döhner H. Stilgenbauer S, et al. Among authors: winkler d. Blood. 2014 May 22;123(21):3247-54. doi: 10.1182/blood-2014-01-546150. Epub 2014 Mar 20. Blood. 2014. PMID: 24652989 Free article. Clinical Trial.
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
Kröber A, Bloehdorn J, Hafner S, Bühler A, Seiler T, Kienle D, Winkler D, Bangerter M, Schlenk RF, Benner A, Lichter P, Döhner H, Stilgenbauer S. Kröber A, et al. Among authors: winkler d. J Clin Oncol. 2006 Feb 20;24(6):969-75. doi: 10.1200/JCO.2005.03.7184. Epub 2006 Jan 17. J Clin Oncol. 2006. PMID: 16418492
838 results